Mounjaro Shortage Guide for Healthcare Providers: Alternatives, Switching Protocols, and Patient Communication

The bottom line for busy clinicians: Mounjaro (tirzepatide) shortages have created real challenges for prescribers managing patients with type 2 diabetes and obesity. This guide covers the current supply landscape, evidence-based switching protocols, prior authorization strategies, and practical tools — including FindUrMeds — to help you keep your patients on track when their prescription is hard to find.

---

The Current Mounjaro Shortage Landscape

Since its FDA approval in 2022, tirzepatide has faced persistent supply constraints driven by demand that significantly outpaced Eli Lilly's manufacturing capacity. The FDA added Mounjaro to its drug shortage database, and while supply has improved incrementally, availability remains inconsistent across dosage strengths — particularly at higher doses (10 mg, 12.5 mg, and 15 mg).

A few things worth knowing as you navigate prescribing decisions:

• Lower doses are more consistently available than higher maintenance doses. Patients mid-titration are often the hardest hit.
• Regional variation is significant. A pharmacy in one ZIP code may have stock while one three miles away has none.
• Compounded tirzepatide flooded the market during the shortage window, but the FDA removed tirzepatide from the shortage list for certain presentations in 2024 — triggering enforcement action against compounding pharmacies. This is an evolving regulatory situation worth monitoring.
• Zepbound (tirzepatide for obesity) and Mounjaro (tirzepatide for type 2 diabetes) are the same molecule but carry different indications, NDC numbers, and formulary coverage. Stock availability and insurance coverage differ between the two, which matters for your patients.

For real-time shortage updates, the FDA Drug Shortages database and ASHP shortage resource center remain the most reliable references.

---

Therapeutic Alternatives: What the Evidence Supports

When Mounjaro is unavailable, you have several options — each with important clinical nuances.

GLP-1 Receptor Agonists (Single-Mechanism)

The most clinically proximate alternatives are the injectable GLP-1 agonists:

• Semaglutide (Ozempic) — FDA-approved for type 2 diabetes; once-weekly subcutaneous injection. Ozempic has faced its own shortage challenges but supply has normalized for most doses. Robust cardiovascular outcomes data (SUSTAIN-6, SELECT trial).
• Semaglutide (Wegovy) — Same molecule as Ozempic but FDA-approved for chronic weight management. Separate formulary coverage pathway.
• Dulaglutide (Trulicity) — Once-weekly GLP-1 agonist; generally more available. Modest efficacy compared to semaglutide or tirzepatide but a reasonable option for patients who are stable and well-controlled.
• Liraglutide (Victoza / Saxenda) — Daily injection. Less preferred due to injection frequency and relatively lower efficacy for weight or glycemic outcomes, but may be accessible when others are not.

SGLT-2 Inhibitors as Add-On or Bridge Therapy

For your type 2 diabetes patients specifically, SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) offer meaningful glycemic benefit, cardiorenal protection, and are generally well-stocked at most pharmacies. They won't replicate GLP-1 mediated weight loss, but they're a reasonable bridge or adjunct while tirzepatide supply is resolved.

For Patients Primarily on Mounjaro for Weight Management

If a patient's primary indication is obesity or weight management and they cannot access tirzepatide, semaglutide (Wegovy) is the most pharmacologically similar alternative with comparable outcomes data. Bupropion/naltrexone (Contrave) and phentermine/topiramate (Qsymia) remain options but offer substantially less efficacy.

---

Switching Protocols: Clinical Considerations

Switching between GLP-1 or GIP/GLP-1 agents requires thoughtful planning. Here are the key clinical considerations:

Timing of the Switch

There is no established washout period required when switching between GLP-1 agonists. However, given the long half-lives of once-weekly formulations (semaglutide's half-life is approximately 1 week; tirzepatide's is approximately 5 days), you should:

• Start the new agent at the lowest available dose regardless of the dose the patient was taking with tirzepatide. GI tolerability at initiation varies by agent, and patients may have developed tolerance to tirzepatide's side effect profile that doesn't transfer directly.
• Wait until the next scheduled dose of tirzepatide would have been due before initiating the new agent, especially for weekly formulations.

Glycemic Monitoring After Switching

Patients switching from tirzepatide — which has dual GIP/GLP-1 activity — may experience a reduction in glycemic control or weight loss momentum when transitioning to a single-mechanism GLP-1 agonist. Advise patients of this possibility and plan for:

• A1C and fasting glucose reassessment at 8–12 weeks post-switch
• Dose titration on the new agent per its approved schedule
• Consideration of adding or adjusting complementary agents (metformin, SGLT-2 inhibitors) if glycemic control slips

Weight Management Patients: Setting Realistic Expectations

Patients who have experienced significant weight loss on tirzepatide may be disappointed by the slower or less pronounced response to alternative agents. This is not a treatment failure — it reflects the unique dual-agonism of tirzepatide. Document your clinical reasoning, set expectations proactively, and frame any alternative as a bridge rather than a permanent substitution when appropriate.

---

Prior Authorization Considerations During Shortages

Shortages create downstream PA headaches. Here's what's worth knowing:

If a patient's PA was approved for Mounjaro and you need to switch agents: Most payers will require a new PA for an alternative agent. Starting that process before the patient runs out of their current supply is critical — don't wait until they're already out.

Step therapy requirements: Many commercial plans and Medicaid programs require step therapy through metformin and/or a sulfonylurea before approving GLP-1 agonists. If your patient is already established on Mounjaro, you may be able to use that history to expedite PA for an alternative.

Shortage documentation in PA appeals: Some payers will accept shortage documentation — such as the FDA's shortage database listing or documented pharmacy denial of stock — as grounds for exceptions or expedited review. Including this with your appeal can strengthen your case.

Zepbound vs. Mounjaro coverage: If your patient has an obesity indication and their plan covers Zepbound but not Mounjaro (or vice versa), it may be worth exploring whether switching the indication or the specific product can resolve a formulary barrier while supply constraints persist.

---

Communicating With Patients About Shortages

One of the most important — and underappreciated — parts of managing drug shortages is the provider-patient conversation. Patients who have experienced meaningful results on tirzepatide can feel frustrated, anxious, or dismissed when supply issues disrupt their care.

What to Say (and Not Say)

Do:

• Acknowledge the inconvenience directly. "I know this is frustrating — this is a real supply issue that's affecting a lot of patients."
• Explain the therapeutic rationale for any switch clearly and in plain language.
• Give patients concrete next steps, not just "check around."
• Let them know you're actively working on the problem, not just sending them to fend for themselves.

Don't:

• Suggest compounded tirzepatide without a clear understanding of the current FDA enforcement landscape and your state's regulations.
• Dismiss concerns about weight regain or glycemic change — these are legitimate clinical concerns, not patient overreaction.
• Assume patients will figure out the insurance piece on their own.

Written Communication

Consider providing patients with a brief written summary of:

• Why their medication is unavailable
• What you're prescribing as an alternative (if applicable)
• What to expect during any transition
• Resources to help them search for their prescription

For guidance on talking points tailored to patients rather than providers, see how to help patients find Mounjaro in stock.

---

How to Use FindUrMeds as a Provider Resource

FindUrMeds is a pharmacy locator service that contacts pharmacies on behalf of patients and identifies in-stock prescriptions across 15,000+ US locations — including CVS, Walgreens, Rite Aid, Walmart, Kroger, Publix, Costco, and Sam's Club — typically within 24–48 hours.

For providers managing patients affected by the Mounjaro shortage, FindUrMeds can serve as a practical referral tool:

• Direct patients to FindUrMeds rather than asking them to call pharmacies individually. The service does the legwork and has a 92% success rate — including for high-demand medications like tirzepatide.
• Recommend it alongside any new prescription. If you're writing a prescription for Mounjaro that the patient may struggle to fill, pointing them to FindUrMeds at the point of prescribing reduces the likelihood of treatment gaps.
• Trusted by 200+ healthcare providers nationwide, FindUrMeds is already part of the workflow for many practices managing patients on GLP-1 and GIP/GLP-1 therapies.

This is not a substitute for clinical decision-making — it's a logistics tool that reduces the burden on both your staff and your patients when supply chains are disrupted. It also reduces the volume of "I can't find my medication" calls your office receives.

For cost-related challenges your patients face in addition to availability, see how to help patients save money on Mounjaro.

---

A Note on Compounded Tirzepatide

This warrants a direct conversation. During the peak of the tirzepatide shortage, FDA-registered 503A and 503B compounders were legally permitted to produce compounded tirzepatide. As FDA has delisted certain tirzepatide formulations from the shortage list, enforcement action against compounders has increased.

As of 2024–2025, the regulatory landscape is shifting rapidly. Before recommending or approving compounded tirzepatide for any patient, verify:

• Current FDA shortage status for the specific dose/formulation
• Your state board of pharmacy's guidance on compounded GLP-1s
• The compounder's 503A/503B registration and compliance status

Patients may ask about compounding — have a clear, current answer ready.

---

Quick-Reference Checklist for Providers

When a patient can't access Mounjaro, here's a practical action sequence:

• Verify current FDA shortage status for the specific dose
• Check whether Zepbound (same molecule, different indication/coverage) is accessible for the patient
• Assess whether a therapeutic switch is clinically appropriate
• Initiate new PA if switching agents
• Counsel patient on what to expect during transition
• Refer patient to FindUrMeds to search available stock before switching
• Document shortage and clinical reasoning in the chart
• Schedule follow-up for glycemic or weight monitoring post-switch

---

Frequently Asked Questions

Can I prescribe Zepbound instead of Mounjaro if my patient's primary diagnosis is type 2 diabetes?

Zepbound is FDA-approved for chronic weight management (BMI ≥30, or ≥27 with a weight-related comorbidity), while Mounjaro is approved specifically for type 2 diabetes. They contain the same active ingredient (tirzepatide) at the same doses, but they carry different indications and are billed and covered differently. Prescribing Zepbound for a patient whose primary diagnosis is type 2 diabetes may create insurance complications. Consult your payer's formulary and document your clinical rationale carefully.

How long can a patient safely go without tirzepatide before there's a meaningful clinical impact?

There's no firm universal threshold, but patients with type 2 diabetes may see glycemic drift within 2–4 weeks, particularly if tirzepatide was their primary agent. Weight regain can begin within weeks for obesity patients. The priority should be minimizing gaps — either by locating supply quickly (tools like FindUrMeds can help) or initiating a bridge therapy promptly.

Is it appropriate to split or stretch doses to extend supply?

This is not a recommended practice. Dose alterations affect both efficacy and tolerability, and patients may experience increased GI side effects or subtherapeutic glycemic control. If supply is critically short, transitioning to an alternative agent at an appropriate starting dose is preferable to uncontrolled dose manipulation.

What should I document in the patient's chart when a shortage forces a therapeutic change?

Document the shortage as the clinical rationale for the switch, the alternative prescribed, the patient counseling provided, and your plan for monitoring and returning to tirzepatide when available. This supports continuity of care and provides clear documentation if a PA appeal or exception request is needed.

---

Need help finding Mounjaro in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Mounjaro Near You →

---

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →